Compare RCMT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | LCTX |
|---|---|---|
| Founded | 1971 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.9M | 251.4M |
| IPO Year | 1997 | 1996 |
| Metric | RCMT | LCTX |
|---|---|---|
| Price | $31.82 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $45.00 | $5.50 |
| AVG Volume (30 Days) | 46.2K | ★ 1.3M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $186,737,000.00 | $14,556,000.00 |
| Revenue This Year | $8.74 | $4.38 |
| Revenue Next Year | $10.00 | $10.80 |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | 5.83 | ★ 53.24 |
| 52 Week Low | $17.26 | $0.88 |
| 52 Week High | $43.68 | $1.99 |
| Indicator | RCMT | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.39 | 43.15 |
| Support Level | $27.02 | $0.89 |
| Resistance Level | $32.39 | $1.18 |
| Average True Range (ATR) | 1.77 | 0.07 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 17.60 | 2.10 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.